Bausch Health Companies Inc. (BHC) Covered Calls
Bausch Health Companies Inc. is a global diversified pharmaceutical company that develops, manufactures, and markets a broad range of products in the gastrointestinal, dermatological, and neurological health sectors. The company operates through several major segments, including Salix Pharmaceuticals and Solta Medical, and maintains a significant controlling interest in Bausch + Lomb Corporation.
You can sell covered calls on Bausch Health Companies Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for BHC (prices last updated Tue 1:15 PM ET):
| Bausch Health Companies Inc. (BHC) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 5.38 | +0.03 | 5.38 | 5.39 | 593K | 13 | 2.0 |
| Covered Calls For Bausch Health Companies Inc. (BHC) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Mar 20 | 5.5 | 0.10 | 5.29 | 1.9% | 63.0% | |
| Apr 17 | 5 | 0.55 | 4.84 | 3.3% | 30.9% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Core Business and Products
Bausch Health (BHC) is a specialty pharmaceutical firm focused on branded products for gastroenterology, dermatology, and neurology. Its most significant asset is the blockbuster drug Xifaxan, used for irritable bowel syndrome and hepatic encephalopathy. The company’s portfolio is organized into several key divisions: Salix (GI health), Ortho Dermatologics (prescription skin care), and Solta Medical (aesthetic devices). Additionally, Bausch Health holds a majority stake in Bausch + Lomb, a global leader in eye health, though it has actively worked toward a full structural separation of that entity to unlock shareholder value.
Competitive Landscape
The pharmaceutical and medical device sectors are highly competitive, featuring global giants with massive research budgets. Bausch Health competes for market share against other specialty and diversified healthcare firms. Key rivals with active options markets on major exchanges include AbbVie Inc. and Pfizer Inc.. In the aesthetic and eye care markets, it faces competition from Alcon Inc. and Johnson & Johnson. For investors tracking the eye-care spin-off specifically, the primary comparison point is Bausch + Lomb Corporation.
Strategic Outlook and Innovation
The company’s strategic priority is deleveraging its balance sheet through cash flow optimization and the potential monetization of its remaining stake in Bausch + Lomb. Innovation efforts are focused on lifecycle management for Xifaxan and the development of next-generation dermatological treatments and aesthetic hardware within the Solta Medical unit. Management is also navigating complex intellectual property litigation and regulatory hurdles related to generic competition. The long-term outlook for BHC depends on its ability to maintain patent protection for its core products while successfully pivoting toward a leaner, more focused corporate structure following its historic reorganization.
| Top 10 Open Interest For Mar 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | QQQ covered calls | 1. | CTMX covered calls | |
| 2. | SLV covered calls | 7. | EWZ covered calls | 2. | PATH covered calls | |
| 3. | EEM covered calls | 8. | FXI covered calls | 3. | FLY covered calls | |
| 4. | SPY covered calls | 9. | GLD covered calls | 4. | RCAT covered calls | |
| 5. | IBIT covered calls | 10. | KWEB covered calls | 5. | S covered calls | |
Want more examples? BHB Covered Calls | BHE Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
